[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @duiliorocha_onc Duilio Rocha Duilio Rocha posts on X about matterhorn, instead of the most. They currently have XXXXX followers and X posts still getting attention that total XX engagements in the last XX hours. ### Engagements: XX [#](/creator/twitter::2918116371/interactions)  - X Week XXX -XX% ### Mentions: X [#](/creator/twitter::2918116371/posts_active)  - X Week X no change ### Followers: XXXXX [#](/creator/twitter::2918116371/followers)  - X Week XXXXX -XXXX% ### CreatorRank: undefined [#](/creator/twitter::2918116371/influencer_rank)  ### Social Influence [#](/creator/twitter::2918116371/influence) --- **Social category influence** [travel destinations](/list/travel-destinations) **Social topic influence** [matterhorn](/topic/matterhorn), [instead of](/topic/instead-of) ### Top Social Posts [#](/creator/twitter::2918116371/posts) --- Top posts by engagements in the last XX hours "Comments on top GI abstracts from #ESMO25 X MATTERHORN Update FLOT Durvalumab in resectable gastric/GEJ adenocarcinoma OS 3y-OS XXXX% vs XXXX% EFS 2y-EFS XX% vs XX% Should we offer it to every patient Thoughts below 👇 @OncoAlert" [X Link](https://x.com/duiliorocha_onc/status/1979210129787457586) [@duiliorocha_onc](/creator/x/duiliorocha_onc) 2025-10-17T15:37Z 1008 followers, XXX engagements "NCCN recommended against periop durva for PD-L1-negative tumors. 💭 My take: that may change. Id consider durva for all patients on FLOT. But id love to see analyses w/ CPS instead of TAP (remember CM-577) alternative PD-L1 cut-offs and a closer look at non-MSI-H disease" [X Link](https://x.com/duiliorocha_onc/status/1979210141288239383) [@duiliorocha_onc](/creator/x/duiliorocha_onc) 2025-10-17T15:37Z 1008 followers, XXX engagements "Advances in periop treatment beautifully shown by Dr. Sylvie Lorenzen-Munich. 2-y OS XX% in Magic control arm vs XX% in D-FLOT MATTERHORN arm. 🏔Were climbing the mountain. #ESMO25 @OncoAlert" [X Link](https://x.com/duiliorocha_onc/status/1979210144668958755) [@duiliorocha_onc](/creator/x/duiliorocha_onc) 2025-10-17T15:37Z 1008 followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@duiliorocha_onc Duilio Rocha
Duilio Rocha posts on X about matterhorn, instead of the most. They currently have XXXXX followers and X posts still getting attention that total XX engagements in the last XX hours.
Engagements: XX #
- X Week XXX -XX%
Mentions: X #
- X Week X no change
Followers: XXXXX #
- X Week XXXXX -XXXX%
CreatorRank: undefined #
Social Influence #
Social category influence travel destinations
Social topic influence matterhorn, instead of
Top Social Posts #
Top posts by engagements in the last XX hours
"Comments on top GI abstracts from #ESMO25 X MATTERHORN Update FLOT Durvalumab in resectable gastric/GEJ adenocarcinoma OS 3y-OS XXXX% vs XXXX% EFS 2y-EFS XX% vs XX% Should we offer it to every patient Thoughts below 👇 @OncoAlert"
X Link @duiliorocha_onc 2025-10-17T15:37Z 1008 followers, XXX engagements
"NCCN recommended against periop durva for PD-L1-negative tumors. 💭 My take: that may change. Id consider durva for all patients on FLOT. But id love to see analyses w/ CPS instead of TAP (remember CM-577) alternative PD-L1 cut-offs and a closer look at non-MSI-H disease"
X Link @duiliorocha_onc 2025-10-17T15:37Z 1008 followers, XXX engagements
"Advances in periop treatment beautifully shown by Dr. Sylvie Lorenzen-Munich. 2-y OS XX% in Magic control arm vs XX% in D-FLOT MATTERHORN arm. 🏔Were climbing the mountain. #ESMO25 @OncoAlert"
X Link @duiliorocha_onc 2025-10-17T15:37Z 1008 followers, XXX engagements